| Literature DB >> 33436955 |
Noboru Takata1,2, Kiyo-Aki Ishii3, Hiroaki Takayama1,4, Mayumi Nagashimada5, Kyoko Kamoshita1, Takeo Tanaka1, Akihiro Kikuchi1, Yumie Takeshita1, Yukako Matsumoto1, Tsuguhito Ota1, Yasuhiko Yamamoto6, Satoshi Yamagoe7, Akihiro Seki2, Yoshio Sakai2, Shuichi Kaneko2, Toshinari Takamura8.
Abstract
It remains unclear how hepatic steatosis links to inflammation. Leukocyte cell-derived chemotaxin 2 (LECT2) is a hepatokine that senses fat in the liver and is upregulated prior to weight gain. The aim of this study was to investigate the significance of LECT2 in the development of nonalcoholic steatohepatitis (NASH). In human liver biopsy samples, elevated LECT2 mRNA levels were positively correlated with body mass index (BMI) and increased in patients who have steatosis and inflammation in the liver. LECT2 mRNA levels were also positively correlated with the mRNA levels of the inflammatory genes CCR2 and TLR4. In C57BL/6J mice fed with a high-fat diet, mRNA levels of the inflammatory cytokines Tnfa and Nos2 were significantly lower in Lect2 KO mice. In flow cytometry analyses, the number of M1-like macrophages and M1/M2 ratio were significantly lower in Lect2 KO mice than in WT mice. In KUP5, mouse kupffer cell line, LECT2 selectively enhanced the LPS-induced phosphorylation of JNK, but not that of ERK and p38. Consistently, LECT2 enhanced the LPS-induced phosphorylation of MKK4 and TAB2, upstream activators of JNK. Hepatic expression of LECT2 is upregulated in association with the inflammatory signature in human liver tissues. The elevation of LECT2 shifts liver residual macrophage to the M1-like phenotype, and contributes to the development of liver inflammation. These findings shed light on the hepatokine LECT2 as a potential therapeutic target that can dissociate liver steatosis from inflammation.Entities:
Year: 2021 PMID: 33436955 PMCID: PMC7804418 DOI: 10.1038/s41598-020-80689-0
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379